Ocular Therapeutix, Inc. (OCUL) financial statements (2022 and earlier)

Company profile

Business Address 24 CROSBY DRIVE
BEDFORD, MA 01730
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments164,164179,281191,860209,378228,05770,64284,294
Cash and cash equivalents164,164179,281191,860209,378228,05770,64284,294
Receivables21,13519,55218,73413,63112,2527,7792,874
Inventory, net of allowances, customer advances and progress billings1,2501,2221,1121,1231,2011,1541,067
Inventory1,2501,2221,1121,1231,2011,1541,067
Other undisclosed current assets4,7513,8774,8174,0004,6502,3282,058
Total current assets:191,300203,932216,523228,132246,16081,90390,293
Noncurrent Assets
Operating lease, right-of-use asset4,8675,1295,3785,6175,8446,0626,269
Property, plant and equipment6,9566,9147,0427,5278,0958,4908,934
Restricted cash and investments1,7641,7641,7641,7641,7641,7641,764
Total noncurrent assets:13,58713,80714,18414,90815,70316,31616,967
TOTAL ASSETS:204,887217,739230,707243,040261,86398,219107,260
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities24,71323,60420,06317,72617,01615,4038,419
Accounts payable4,5924,2463,8814,1522,7093,2382,650
Accrued liabilities20,12119,35816,18213,57414,30712,1655,769
Debt   8,2908,2906,2065,384
Other undisclosed current liabilities1,6241,5541,4871,4211,3581,297 
Total current liabilities:26,33725,15821,55027,43726,66422,90613,803
Noncurrent Liabilities
Long-term debt and lease obligation57,35957,17757,00946,89848,79150,67555,578
Long-term debt, excluding current maturities51,43550,82250,23939,72941,24342,76647,322
Operating lease, liability5,9246,3556,7707,1697,5487,9098,256
Liabilities, other than long-term debt33,19248,06471,90185,297110,31328,76432,535
Deferred revenue13,00012,00012,00012,00012,000  
Derivative instruments and hedges, liabilities20,19236,06459,90173,29798,31328,76432,535
Total noncurrent liabilities:90,551105,241128,910132,195159,10479,43988,113
Total liabilities:116,888130,399150,460159,632185,768102,345101,916
Stockholders' equity
Stockholders' equity attributable to parent87,99987,34080,24783,40876,095(4,126)5,344
Common stock8888866
Additional paid in capital633,795629,286624,850619,530615,338449,507447,033
Accumulated deficit(545,804)(541,954)(544,611)(536,130)(539,251)(453,639)(441,695)
Total stockholders' equity:87,99987,34080,24783,40876,095(4,126)5,344
TOTAL LIABILITIES AND EQUITY:204,887217,739230,707243,040261,86398,219107,260

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues12,30812,15311,7187,3427,3495,8761,569
Cost of revenue
(Cost of Goods and Services Sold)
(1,108)(1,310)(1,096)(892)(680)(450)(134)
Gross profit:11,20010,84310,6226,4506,6695,4261,435
Operating expenses(29,249)(30,372)(30,853)(26,678)(21,012)(19,432)(19,319)
Operating loss:(18,049)(19,529)(20,231)(20,228)(14,343)(14,006)(17,884)
Nonoperating income (expense)14,19922,18611,75023,349(71,269)2,062(18,684)
Interest and debt expense(1,680)(1,658)(1,655)(1,679)(1,726)(1,715)(1,694)
Income (loss) before gain (loss) on sale of properties:(5,530)999(10,136)1,442(87,338)(13,659)(38,262)
Other undisclosed net income1,680  1,6791,726  
Net income (loss):(3,850)999(10,136)3,121(85,612)(13,659)(38,262)
Other undisclosed net income attributable to parent 1,6581,655  1,7151,694
Net income (loss) available to common stockholders, basic:(3,850)2,657(8,481)3,121(85,612)(11,944)(36,568)
Interest on convertible debt1,1231,1131,0951,078 1,069 
Dilutive securities, effect on basic earnings per share(15,872)(23,837)(13,396)(25,016) (3,771) 
Net loss available to common stockholders, diluted:(18,599)(20,067)(20,782)(20,817)(85,612)(14,646)(36,568)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net income (loss):(3,850)999(10,136)3,121(85,612)(13,659)(38,262)
Comprehensive income (loss), net of tax, attributable to parent:(3,850)999(10,136)3,121(85,612)(13,659)(38,262)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: